The stocks listed below yield between 2.7% and 3.5%.
They are in different sectors of the economy and can help diversify your portfolio while also generating plenty of recurring cash flow.
10 stocks we like better than AbbVie ›
Want some quality income-generating investments you can put in your portfolio for the long term, and not worry about? The stocks listed below check off those boxes and can make for ideal investments to buy and hold. Not only do they offer high yields today, but they’ve also been growing their payouts for decades.
AbbVie (NYSE: ABBV), Home Depot (NYSE: HD), and ExxonMobil (NYSE: XOM) can diversify your portfolio while also setting you up to generate plenty of recurring cash flow for the long term. Here’s a closer look at them, and why they’re among the best dividend stocks you can buy today.
Image source: Getty Images.
Pharma stock AbbVie pays investors a yield of around 2.9% right now, which is more than double the S&P 500 average of 1.2%. The company spun off from Abbott Laboratories back in 2013, and when including its streak as part of that business, it spans more than 50 straight years, which means AbbVie is a Dividend King.
The company’s most recent increase is a 5.5% boost to its payout in light of its strong financial results. Since splitting off from Abbott Labs, AbbVie has increased its quarterly dividend payments by over 330%. AbbVie hasn’t simply been boosting the dividend to keep its streak going; it has been making meaningful rate hikes for its shareholders.
Through the first nine months of the year, the company has demonstrated strong growth with sales rising by 8%, to $44.5 billion. Humira is no longer its top-selling drug, but AbbVie has been able to pivot to other drugs, with Skyrizi and Rinvoq generating a combined $18.5 billion through the first three quarters, well above Humira’s current quarterly tally of $3.3 billion.
With a diverse mix of drugs treating various diseases and conditions, AbbVie is one of the most robust and safest dividend stocks you can find in the…
..
